Form 4: Heron Therapeutics CEO Acquires Shares

Heron Therapeutics CEO Craig Collard acquired 34,789 common shares through the vesting of restricted stock units.

Summary

• Craig Collard, Chief Executive Officer and Director of Heron Therapeutics, acquired 34,789 shares of common stock.
• The acquisition occurred on July 31, 2025, through the vesting of Restricted Stock Units (RSUs).
• Each restricted stock unit represents a contingent right to receive one share of common stock.
• Following this transaction, Collard directly holds 474,538 shares of common stock.
• He also holds 487,042 Restricted Stock Units.
• The Restricted Stock Units vest in 16 equal installments, with vesting commencing one quarter after the grant date of January 31, 2025.

Sentiment

Score: 7

Explanation: The transaction reflects the vesting of executive compensation, leading to an increase in direct share ownership by the CEO. This is a routine and expected event, generally viewed as neutral to slightly positive as it aligns management's interests with shareholders.

Positives

• CEO Craig Collard increased his direct ownership of common stock, which can signal confidence in the company's future.
• The acquisition was through the vesting of Restricted Stock Units, indicating a compensation-related event rather than an open market purchase, which is a standard part of executive compensation.

Future Outlook

This filing is a transaction report and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing details an insider transaction, specifically the vesting of executive compensation in the form of restricted stock units. Such transactions are common across all industries as part of standard executive compensation packages and do not inherently reflect broader industry trends or competitive dynamics.

Comparison to Industry Standards

• The vesting of restricted stock units and subsequent acquisition of common stock by a CEO is a standard practice in executive compensation across various industries, including biotechnology and pharmaceuticals. This transaction aligns with typical equity incentive structures designed to align management interests with shareholder value. Specific comparable companies or projects are not relevant for this type of insider transaction report.

Stakeholder Impact

• Shareholders: Increased direct ownership by the CEO may be viewed positively as it aligns management's interests with shareholder value.
• Employees: The transaction is part of executive compensation, which is a standard practice for incentivizing key personnel.

Next Steps

• Remaining Restricted Stock Units will continue to vest in 16 equal installments, commencing one quarter after January 31, 2025.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction involving the vesting of restricted stock units for the CEO. While it increases the CEO's direct ownership, it is a pre-scheduled compensation event rather than an open market purchase or sale driven by new information. Therefore, it does not provide new fundamental insights that would significantly alter an investment thesis, warranting a 'hold' recommendation.

Keywords

Heron Therapeutics, HRTX, Craig Collard, CEO, Director, Stock Acquisition, Restricted Stock Units, Insider Transaction, Executive Compensation